BioSpace News Archive

Elligo Health Research is proud to welcome Michael Gibertini, Ph.D. , to its leadership team. Gibertini joins the team at the healthcare-enabling company as the new chief development officer and will develop new lines of business to support Elligo’s mission to bring clinical research as a care option to patients. An industry veteran, Gibertini brings over 30 years of experience to Elligo. His unique strength moldin

RubiconMD, the leading eConsult provider, announced the launch of its new pharmacy offering, RubiconRx, designed to bridge the gap between primary care and clinical pharmacy and provide patients access to the medication support they need.

Recursion’s acquisition supplements its digital drug discovery vertical, further enabling its pipeline of four clinical and over 30 discovery programs

Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for solid and liquid tumors, today announced that it will present new clinical data at the LifeSci Partners Private Company Virtual Summer Symposium on August 5, 2020. “We have seen a 71% Overall Response Rate with 14% Complete Response in seven metastatic colon cancer patients

Publication of the Phase 2 U.S. study data show that RHB-102 (Bekinda ® ) 12mg delivers a clinically meaningful improvement in overall stool consistency response versus placebo in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), meeting the study’s primary endpoint -- In addition, the publication highlights that elevated baseline C-reactive protein (CRP) may be used to identify treatment responders in this complex disease, which lacks reliable predictive markers -- T

Businesses owe it to their employees and customers to provide them with an environment that is as protected from viruses as possible.

Bergenbio in late stage set-up phase to sponsor and conduct a clinical study using bemcentinib in a country of high COVID-19 incidence

Evolve BioSystems announced today that Dr. Minhthy Nguyen , PhD, has joined the company as Senior Vice President, Research & Development. Dr. Nguyen joins the company in anticipation of the pending announcement of positive results from several large clinical studies, positioning the company for a material leap forward in the infan

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a preclinical study evaluating mRNA-1273, its vaccine candidate against COVID-19, was published in The New England Journal of Medicine.

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will provide a corporate update and report financial results for the second quarter ended June 30, 2020 on Tuesday, August 11, 2020.